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A B S T R A C T
Atherosclerosis, a chronic inﬂammatory disorder of medium and large arteries and an underlying cause of
cardiovascular disease (CVD), is responsible for a third of all global deaths. Current treatments for CVD, such as
optimized statin therapy, are associated with considerable residual risk and several side eﬀects in some patients.
The outcome of research on the identiﬁcation of alternative pharmaceutical agents for the treatment of CVD has
been relatively disappointing with many promising leads failing at the clinical level. Nutraceuticals, products
from food sources with health beneﬁts beyond their nutritional value, represent promising agents in the pre-
vention of CVD or as an add-on therapy with current treatments. This review will highlight the potential of
several nutraceuticals, including polyunsaturated fatty acids, ﬂavonoids and other polyphenols, as anti-CVD
therapies based on clinical and pre-clinical mechanism-based studies.
1. Introduction
Cardiovascular disease (CVD) accounts for about 31.5% of all global
deaths [1]. An estimated 92.1 million US adults have CVD and it is
expected that this will increase to 43.9% of the adult population by
2030 due to a rise in obesity and diabetes, thereby imposing a greater
burden on the healthcare services [1].
Atherosclerosis, an inﬂammatory disorder of the vasculature, is the
major underlying cause of CVD [2]. Atherosclerosis is initiated by en-
dothelial dysfunction predominantly due to the accumulation of apo-
lipoprotein (Apo)B containing lipoproteins, particularly low-density
lipoprotein (LDL) [2]. Endothelial cell dysfunction leads to the in-
ﬁltration of LDL particles and their subsequent oxidation to oxidized
LDL (oxLDL). In addition, there is an increase in both the secretion of
chemokines from the cells and the expression of adhesion proteins on
their surface that triggers the recruitment of immune cells, particularly
monocytes [2]. The monocytes then diﬀerentiate into macrophages,
which take up modiﬁed LDL to transform into foam cells [2,3]. Over
time, foam cells undergo apoptosis and necrosis and this coupled with
their defective clearance (eﬀerocytosis) leads to the formation of a
lipid-rich necrotic core associated with a chronic inﬂammatory re-
sponse mediated by a range of cytokines [4,5]. The lipid-rich core is
covered by a ﬁbrous cap formed by the extracellular matrix (ECM)
produced by smooth muscle cells that proliferate and migrate from the
media into the intima [2]. The ﬁbrous cap provides lesion stability and
excessive degradation of the ECM due to increased expression and ac-
tivity of a range of proteases in response to inﬂammatory mediators
causes plaque rupture, subsequent thrombotic events and clinical
complications of atherosclerosis [3].
Although the diﬀerent stages in the pathogenesis of atherosclerosis
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are all promising therapeutic targets, major success has emerged from
agents that control lipid homeostasis. Statins that lower LDL-cholesterol
(LDL-C) and have additional pleiotropic eﬀects are widely used [6].
However, there is a considerable residual risk of CVD in patients on
statin therapy with some individuals unable to achieve target LDL-C
goals even with high doses or are intolerant to the drug [6]. High dose
statin therapy is also occasionally associated with side eﬀects such as
non-allergic rhinitis, rhabdomyolysis and hyperglycemia though some
of these are debatable [7]. Substantial research has therefore been
carried out on alternative therapies with some recent successes. For
example, ezetimibe, an inhibitor of intestinal Niemann-Pick C1-like
protein, which is involved in the uptake of dietary cholesterol, has
shown some promise in lowering plasma LDL-C and in improving car-
diovascular outcomes as demonstrated by some recent trials: Improved
Reduction of Outcomes: Vytorin Eﬃcacy International Trial (IMPROVE-
IT) [8]; Plaque Regression With Cholesterol Absorption Inhibitor or
Synthesis Inhibitor Evaluated by Intravascular Ultrasound (PRECISE-
IVUS) [9]; and Multicenter Randomized Study of ROsuvastatin and
eZEtimibe (MRS-ROZE) [10]. Inhibition of proprotein convertase sub-
tilisin/kexin type 9 (PCSK9), which binds to the LDL receptor (LDLR)
and targets it for lysosomal degradation, is also eﬀective in reducing
LDL-C and cardiovascular events [11]. Several Phase III clinical trials
were initiated on three PCSK9 antibodies, evolocumab, alirocumab and
bococizumab [11]. The outcome of the Further Cardiovascular Out-
comes Research With PCSK9 Inhibition in Subjects With Elevated Risk
(FOURIER) trial on evolocumab involving 27,564 patients demon-
strated CVD beneﬁt from lowering of LDL-C levels below current targets
[12]. On the other hand, the sponsors stopped the trials on bococi-
zumab early due to high rates of antidrug antibodies [13]. Nevertheless,
signiﬁcant beneﬁts were seen in high-risk patients [14]. Other avenues
for inhibiting PCSK9 actions are also being pursued; for example, sus-
tained reduction of LDL-C has recently been shown for Inclisiran, a
long-acting synthetic small-interfering RNA that selectively targets
PCSK9 [15].
The successes detailed above have been outnumbered by dis-
appointing outcomes on many promising pharmaceutical agents [16].
Despite the extensive evidence associating increased plasma high-den-
sity lipoprotein (HDL) levels with a reduced risk of CVD, clinical trials
using orally active, HDL raising agents have largely failed [17]. Clinical
trials on inhibitors of cholesteryl ester transfer protein have also been
disappointing [17]. Due to atherosclerosis being an inﬂammatory dis-
order, approaches that dampen inﬂammation are also being pursued
[4]. Promising outcomes were recently obtained with the Canakinumab
Anti-inﬂammatory Thrombosis Outcomes Study (CANTOS) that eval-
uated the potential of attenuating inﬂammation using a neutralizing
interleukin (IL)-1β antibody, in order to reduce cardiovascular events in
patients with prior myocardial infarction (MI) [18]. Similarly, the
Cardiovascular Inﬂammation Reduction Trial (CIRT) is investigating
the anti-inﬂammatory potential of low dose methotrexate [4]. It should
however be noted that because of the risks associated with manip-
ulating systemic inﬂammation (e.g. predisposition to infections), such
approaches will have to be restricted to high risk patients until eﬀective
technologies to target them to the atherosclerotic lesions are developed.
Such issues together with the disappointing outcomes on numerous
pharmaceuticals detailed above, and the anticipated future increase in
CVD-burden due to global raise in risk factors such as obesity and
diabetes, highlight the urgent need for more research on alternative
agents in the prevention and treatment of atherosclerosis.
Diets rich in fruit, vegetables, ﬁsh, cereal grains or olive oil have all
been associated with cardiovascular health beneﬁts [19]. Nu-
traceuticals, products derived from food sources that have health ben-
eﬁts beyond their nutritional value, have recently generated substantial
interest in the prevention of atherosclerosis and as an add-on to current
therapies for several reasons. Because nutraceuticals are derived from
food sources, they generally do not suﬀer from the same issues of tol-
erability and safety that are often associated with pharmaceuticals
especially given the long-term use required for the management of risk
factors for CVD. In addition, nutraceuticals often have pleotropic eﬀects
with inhibitory actions on multiple pro-atherogenic changes thereby
making them the agents of choice in conjunction with pharmaceutical
drugs or other lifestyle changes. Nutraceuticals would be particularly
useful for individuals that either have borderline risk factors for CVD,
where there is likely to be particular reluctance to take pharmaceuticals
due to various side eﬀects, or are intolerant to drugs (e.g. statins) or
have other issues such as sarcopenia. Furthermore, nutraceuticals may
be more cost-eﬀective add-on therapies for the management of dysli-
pidemia and other CVD risk factors for many individuals on current
therapies (e.g. statins and/or ezetimibe) compared to more powerful
but expensive alternatives that are in development (e.g. antibodies
against PCSK9 and other proteins).
Unfortunately, despite the promise detailed above, nutraceutical
research has considerably lagged that on pharmaceutical agents on two
key aspects, deeper mechanistic insight and large clinical trials. This is
also reﬂected by the general paucity of published literature on nu-
traceuticals in the cardiovascular ﬁeld compared to that on pharma-
ceuticals. The purpose of this review is to highlight some of the most
promising nutraceuticals that are emerging as potential treatments and
preventatives of atherosclerosis disease development. We discuss the
eﬀects of these nutraceuticals on clinical outcomes and provide both
pre-clinical and mechanism-based studies where appropriate. Due to
space limitations, we have been unable to address the outcomes of all
published literature on these nutraceuticals. Nevertheless, we have
tried to provide a balanced coverage taking both positive and negative
evidence into account together with possible directions that should
form the focus of future studies. Key outcomes from human studies on
the major nutraceuticals addressed in this review are shown in Table 1.
Some of the discrepancies seen in the literature reﬂect diﬀerences in the
size and composition of the participants (e.g. mix of healthy, obese and
patients with high risk for CVD), dose of the agent and duration of the
intervention. Overall, epidemiological studies only indicate associations
that are not necessarily causal with cohort studies being more in-
formative and clinical trials providing the highest level of evidence.
Considerations of the mechanisms of action of dietary components add
to the plausibility of the results from the various studies. Fig. 1 there-
fore provides a summary of the steps in the pathogenesis of athero-
sclerosis where some of the nutraceuticals exert their actions and these
are dealt in more detail in the relevant section of the review. In general,
a given nutraceutical dampens multiple pro-atherogenic events rather
than drastically inhibiting one or a few as is the case with pharma-
ceutical agents. There are of course many other nutraceuticals that have
been less well studied and are therefore not addressed here in detail
because of space constraints. Table 2 lists some of these other emerging
nutraceuticals with a brief summary of their actions.
2. Antioxidant vitamins: great promise but major
disappointments
The oxidation of LDL and the production of free radicals within the
endothelium is a key early pro-atherogenic event and might also play
important roles at later stages of the disease [2,3]. Appropriate dietary
modiﬁcations or supplementation with agents that prevent LDL oxida-
tion may therefore aid in managing the risk of CVD. Throughout the
1990s, antioxidant vitamins were at the forefront of research into the
prevention of CVD. The beneﬁcial eﬀects of three main types of anti-
oxidant vitamins; beta-carotene, Vitamin C and Vitamin E, have been
investigated in numerous animal studies and human trials. These are
essential vitamins as they cannot be produced or stored by the body and
therefore must be acquired in the diet from fruit and vegetables or from
supplements [20].
Pre-clinical studies on all antioxidant vitamins showed great pro-
mise in demonstrating an inverse relationship with CVD risk factors/
events [20]. However, results from clinical trials have been less
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consistent and somewhat disappointing [20]. A large, randomized
controlled Physicians Health Study II, involving 14,641 men, in-
vestigated the role of vitamins C and E independently and as a multi-
vitamin on a number of CVD outcomes over a period of 8 years [21].
The study found no positive eﬀects on CVD outcomes in any of the
treatment groups in comparison to the placebo control. In fact, Vitamin
E supplementation caused increased risk of haemorrhage and stroke
[21]. The outcome of the Supplementation en Vitamines et Mineraux
Antioxydant (SU.VI.MAX) subset trial involving 1162 men and women
also supports the lack of cardiovascular protective eﬀects of antioxidant
supplementation [22]. The percentage of subjects with carotid plaques
was higher following intervention despite reduced arterial stiﬀness as
indicated by pulse wave velocity (PWV) [22]. Other studies, such as the
Vitamin E Atherosclerosis Prevention Study (VEAPS) showed that in
low risk individuals, vitamin E supplementation had no impact on CVD
outcomes over a 3-year follow-up period despite reduction in LDL
oxidation [23]. In addition, no signiﬁcant reductions in 5-year
mortality from incidence of any type of vascular disease were found in a
large randomized, placebo-controlled trial of 20,536 adults (aged
40–80 years) with coronary disease, other occlusive arterial disease or
diabetes involving antioxidant vitamin supplementation (600mg vi-
tamin E, 250mg vitamin C and 20mg beta-carotene daily) [24]. Si-
milarly, no beneﬁt of vitamin E was seen in the GISSI (Gruppo Italiano
per lo Studio Sopravvivenza nell'infarto)-Prevenzione trial [25] (see
Section 3 for more details on this trial). In contrast, the Antioxidant
Supplementation in Atherosclerosis Prevention (ASAP) trial involving
520 men and postmenopausal women showed some positive outcomes
after receiving both vitamin C and E supplementation for 3 years [26].
The progression of common carotid atherosclerosis was retarded in men
who were regular smokers. In addition, the authors suggested that this
could be generalizable to all men and did not rule out a small beneﬁt to
women [26]. This latter proposition has some support from the Wo-
man's Health Study on vitamin E supplementation involving 39,876
healthy US women [27]. In the 10-year follow-up period, there was a
Table 1
Summary of major ﬁndings from human studies.
Nutraceutical Trial name/ﬁrst author Number of participants Study type Major ﬁndings Ref
Vitamins Physicians' Health Study II 14,641 CL No positive eﬀects of Vitamins C or E on any major CVD outcomes
Vitamin E increased risk of stroke
21
SU.VI.MAX subset 1162 CL Vitamin C and E increased number of plaques and decreased pulse wave velocity 22
VEAPS 353 CL No cardiovascular protective eﬀects observed following vitamin E
supplementation
23
MRC/BHF Heart Protection Study 20,536 CL No beneﬁt of Vitamin C, E and beta-carotene supplementation 24
GISSI-Prevenzione 11,324 CL No beneﬁt of vitamin E 25
ASAP 520 CL Vitamin C and E reduced carotid artery atherosclerosis in smoking men 26
Woman's Health Study 39,876 CL 24% reduction in CVD mortality in women receiving vitamin E 27
Karppi et al. 840 EP High serum carotenes is protective in early atherosclerosis 29
Omega-3 GISSI-Prevenzione 11,324 CL 15% reduction in total number of deaths and non-fatal CVD-related events
45% reduction in sudden cardiac deaths
25
JELIS 18,645 CL 19% reduction in major CVD-related events
Most eﬀective as a secondary preventative
33
MAGMA 600 CL Lowered TG, VLDL and oxLDL levels
No additional beneﬁt to those already taking lipid lowering therapies
35
OMEGA 3851 CL No cardiovascular protective eﬀects observed after 1-year follow-up 36
ORIGIN 12,536 CL No cardiovascular protective eﬀects observed after 6-years follow-up 37
MARINE 229 CL Lowered TG levels 38
ANCHOR 702 CL Lowered TG, non-HDL, LDL and total cholesterol levels in statin receiving
patients
39
REDUCE-IT 8000 CL To be completed in 2018 41
STRENGTH 13,000 CL To be completed in 2019 42
Omega-6 OPTILIP 258 CL Optimization of Omega 6:3 Ratio to 3:1 reduces TG and LDL levels 54
Katan et al. 340,000 EP Replacement of saturated fats with PUFA reduces CVD risk 49
Oh et al. 78,778 EP Inverse relationship between PUFA and CVD in women with BMI over 25 50
Laaksonen et al. 1551 EP Linoleic acid is cardio protective and reduces overall mortality 51
Tomiyama et al. 2206 EP Serum CRP levels correlate with increased omega-6 serum levels. 53
Polyphenols EUROLIVE 200 CL Correlation between polyphenol intake and plasma HDL levels
Reduced TG and oxidative stress markers
64
Tjelle et al. 134 CL Reduced blood pressure 60
Shema-Didi et al. 101 CL Reduced blood pressure and improved lipid proﬁle in hemodialysis patients 61
Panahi et al. 117 CL Improved inﬂammatory and oxidative condition of metabolic syndrome patients 65
Ras et al. 70 CL No change in blood pressure 62
Bondia-Pons et al. 78 CL No change in blood pressure 63
PREDIMED 7172 CH Increased polyphenol intake resulted in a reduced mortality risk 70
PREDIMED subset 200 CH Polyphenol intake reduced blood pressure and increased plasma NO levels 71
PREDIMED subset 573 CH Reduced blood pressure in elderly individuals
Decreased TG levels but no changes in total cholesterol, HDL or LDL levels
72
PREDIMED subset 1139 CH Reduced plasma levels of several inﬂammatory biomarkers 73
Flavonoids CoCoA 90 CL Reduced blood pressure and lipid peroxidation 90
Flaviola Health study 100 CL Increased FMD and plasma HDL levels
Decreased blood pressure, arterial stiﬀness, total and LDL cholesterol levels
91
PREDIMED 7172 CH Increased ﬂavanol intake correlated with reduced CVD risk 69
Rassaf et al. 57 CL Improved FMD and reduced blood pressure 84
The Zutphen Elderly Study 805 CH Reduced mortality from CHD and incidence of MI 79
The Caerphilly Study 1900 CH No change in incidence of ischemic heart disease 81
Fiber Ramos et al. 116 CL No additional beneﬁt when combined with other lipid lowering therapies 96
Merchant et al. 46,032 EP Increased ﬁber intake associated with reduced peripheral arterial disease risk 93
Oh et al. 78,779 EP Increased ﬁber intake reduced the risk of stroke in women 94
Liu et al. 39,876 EP Increased ﬁber consumption was correlated with reduced CVD risk 95
See text for further details on these studies, including dosage, trial duration, intervention type and the type of populations. CH, cohort study; CL, clinical trial; EP, epidemiological study.
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signiﬁcant 24% reduction in cardiovascular death in the supplement
group [27]. Inverse correlation was also found between carotenoid
antioxidant supplementation and common carotid artery intima-media
thickness in 1212 elderly Finnish men [28]. More recently, in 840
middle-aged men from Eastern Finland, high serum carotenoid con-
centration was found to be protective against early atherosclerosis [29].
Despite a large number of trials that have taken place over the last
20 years, conﬂicting outcomes make it diﬃcult to determine any ben-
eﬁcial eﬀects of antioxidant therapies. A major limitation is diﬀerences
in the selection criteria of participants for these trials such as gender,
existing risk factors for CVD and ethnicity. These aspects need to be
taken into consideration in future trials to delineate the potential of
antioxidant vitamins in the prevention of CVD.
3. Omega-3 polyunsaturated fatty acids
During normal physiological conditions, the synthesis of eicosa-
noids, inﬂammatory response intermediaries, as well as the regulation
of blood pressure and clotting can be inﬂuenced by polyunsaturated
fatty acids (PUFAs) [30]. Dietary intake of some PUFAs is essential
because they cannot be synthesized in vivo. Omega-3 PUFAs are re-
garded as anti-inﬂammatory and exert their eﬀects via multiple me-
chanisms, including disruption of lipid rafts, altered cell membrane
phospholipid composition, modulation of activation of key transcrip-
tion factors and signaling pathways, and the ability to bind to G protein-
coupled receptor (GPR) 120 [30]. Indeed, omega-3 PUFAs ameliorate
atherosclerosis and even cause plaque regression in mouse model sys-
tems via several mechanisms such as lowering plasma cholesterol le-
vels, alteration of monocyte subsets and their recruitment to lesions,
and modulation of dendritic cell phenotype [31,32].
Over the last 20 years, two large trials, GISSI-Prevenzione and Japan
Eicosapentaenoic acid Lipid Intervention Study (JELIS), have in-
vestigated the potential cardiovascular protective eﬀects of omega-3
PUFAs [25,33]. During the GISSI-Prevenzione trial, 11,324 patients
who had suﬀered a recent MI were randomized between 4 treatment
groups; vitamin E, omega-3 PUFA supplementation, both or control
[25]. At the 3.5-year follow-up, there was a signiﬁcant 15% reduction
in the number of deaths and non-fatal CVD-related events between the
omega-3 receiving group and the control group. In addition, there was a
45% reduction in sudden cardiac deaths [25]. The JELIS trial involved
18,645 hypercholesterolaemic participants who received statins or ei-
cosapentaenoic acid (EPA; an omega-3 PUFA) in combination with
statins [33]. In patients with history of coronary artery disease (sec-
ondary prevention group), a signiﬁcant 19% reduction in the number of
major coronary events was observed in the participants taking EPA
compared to the statin only group after an average 4.6-year follow-up.
In patients with no history of coronary artery disease (primary pre-
vention group), EPA reduced major coronary events by 18% though this
was not signiﬁcant [33]. Although these trials have shown omega-3
PUFAs to potentially exert cardiovascular protective eﬀects both alone
and in combination with statins, it is important to note that these were
performed in a single country before current omega-3 dietary guide-
lines were introduced [34]. Consequently, any diﬀerences between
countries (i.e. diet) can aﬀect the outcomes and therefore they should
be seen to provide encouraging but not irrefutable evidence for the
beneﬁts of omega-3 PUFA consumption [34].
More recent trials, including Multi-Analyte, Genetic, and
Thrombogenic Markers of Atherosclerosis (MAGMA) [35], Eﬀect of
Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After
Myocardial Infarction (OMEGA) [36] and Outcome Reduction with an
Initial Glargine Intervention (ORIGIN) [37], have failed to ﬁnd any
additional cardiovascular beneﬁts from taking omega-3 PUFAs in
combination with traditional therapies. The MAGMA trial involved 600
participants who were randomly assigned to receive ﬁsh oil supple-
mentation only or in combination with their lipid lowering therapy
[35]. Within the total population, ﬁsh oil consumption reduced levels of
triacylglycerol (TG), very low-density lipoprotein (VLDL) and oxLDL
but not in those patients already receiving lipid-lowering therapy [35].
Both the OMEGA and ORIGIN studies used omega-3 ethyl esters inter-
vention in 3851 and 12,536 high-risk patients respectively [36,37].
Unfortunately, neither study was able to observe any additional cardi-
ovascular protective eﬀects from omega-3 PUFA intervention. How-
ever, a major limitation of these studies was the low dose of omega-3
PUFAs used together with participants that had relatively normal levels
of TG (a risk factor for CVD) [2,3,34].
The eﬀect of omega-3 PUFAs in participants with elevated TG levels
was assessed in two preliminary trials known as Multi-center, Placebo-
controlled, Randomized, Double-blind, 12 week study with an Open-
label Extension (MARINE) and Eﬀect of AMR101 (Icosapent Ethyl) on
Triglyceride Levels in Patients on Statins With High Triglyceride Levels
(≥200 and<500mg/dL) (ANCHOR) [38,39]. Omega-3 PUFAs in the
form of EPA ethyl ester decreased TG levels together with other lipid
parameters without increasing LDL levels [38,39]. The two trials also
detected a reduction in several markers of inﬂammation [40]. These
ﬁndings formed part of the rationale to perform a large international
trial known as Reduction of Cardiovascular Events with EPA – Inter-
vention Trial (REDUCE-IT) [34,41]. The trial is expected to be com-
pleted in 2018 and has involved approximately 8000 hypertriglyceri-
demic participants spread over 11 countries. Participants have received
icosapent ethyl (a puriﬁed EPA ethyl ester) in combination with statins
for 6.5 years [34,41]. Another large ongoing international trial called
STatin Residual Risk Reduction With EpaNova in HiGh CV Risk Pa-
tienTs With Hypertriglyceridemia (STRENGTH) on approximately
13,000 patients from 22 countries is assessing the eﬀect of omega-3
carboxylic acids in combination with statins in participants with hy-
pertriglyceridemia [42]. The trial is expected to be completed in 2019.
It is hoped that these studies will provide more substantial evidence on
whether omega-3 PUFA supplementation is capable of providing addi-
tional cardiovascular protective eﬀects when taken in combination with
statins.
Table 2
Other emerging nutraceuticals and their potential beneﬁts.
Nutraceutical Summary of ﬁndings Ref
Allicin Attenuated atherosclerosis in mouse model systems. Garlic supplementation in human trials produced short-term reduction in plasma levels
of LDL, total cholesterol and TG
113–114
Berberine Reduced plaque size, inﬂammation and oxidative stress in ApoE deﬁcient mice. Decreased plasma levels of total cholesterol and LDL in
human studies
115–119
Butyrate Reduced atherosclerosis and oxidative stress in ApoE deﬁcient mice 101, 102
Carnosine No changes in serum cholesterol and CRP levels or blood pressure in humans. Reduced vascular inﬂammation and foam cell formation, as
well as a decrease in serum TG levels in ApoE deﬁcient mice
121–124
Coenzyme Q10 Attenuated atherosclerosis in ApoE deﬁcient mice and promoted cholesterol eﬄux and endothelial function in human subjects 127–129
Curcumin Multiple anti-atherogenic actions in mouse model systems and decreased C-reactive protein levels in human studies 66–68
Lycopene Reduced levels of LDL and pro-inﬂammatory cytokines in human subjects 125, 126
Phytosterols Attenuated atherosclerosis in mouse model systems and reduced plasma LDL in human subjects 130–134, 136–137
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4. Omega-6 polyunsaturated fatty acids
In terms of cardiovascular health, the roles of omega-3 and omega-6
PUFAs are generally considered antagonistic, with the former regarded
as anti-inﬂammatory and the latter as pro-inﬂammatory. The recent
increased consumption of omega-6 PUFA-rich vegetable oils has altered
the ideal omega-6:omega-3 PUFA ratio from 4:1 to approximately 15:1,
which has been linked to an increase in inﬂammatory disorders [43].
The American Heart Association therefore recommends consumption of
at least 200 g of oily ﬁsh a week in order to reduce the omega-6:omega-
3 PUFA ratio [44]. However, not all omega-6 PUFAs are pro-in-
ﬂammatory with both gamma-linolenic acid (GLA) and dihomo-
gamma-linolenic acid (DLGA) reducing inﬂammation [45] and acting in
an anti-atherogenic manner in mouse model systems [46,47]. However,
the published literature relating to omega-6 PUFAs and CVD in humans
remains conﬂicting [48].
Pooled data from 11 cohort studies (340,000 individuals) showed
that a reduction in the consumption of saturated fats replaced with a
proportionally higher intake of omega-6 PUFAs signiﬁcantly decreased
coronary heart disease (CHD) [49]. This conclusion is also supported by
several other studies in both men and women which have shown
omega-6 PUFA levels to be inversely associated with CVD risk and
death [50,51]. A prospective Nurses' Health Study on 78,778 women
showed an inverse association between the intake of the omega-6
PUFA, linoleic acid, and the risk of CHD [50]. A prospective population-
based study, Kuopio Ischaemic Heart Disease Risk Factor (KIHD), on
1551 middle-aged men over a 15-year follow-up also demonstrated
substantial cardioprotective beneﬁts of linoleic acid and a reduction in
overall mortality [51]. A much smaller human study also showed a
positive impact of GLA in decreasing levels of TG (by 48%) and in-
creasing HDL (by 22%) [52]. However, not all human studies support a
beneﬁcial role for omega-6 PUFAs in the prevention of CVD. For ex-
ample, a study of 2206 healthy Japanese men showed that high serum
levels of omega-6 PUFAs was associated with elevated CRP, suggesting
an unfavorable inﬂammatory proﬁle [53]. Many studies have in-
vestigated the impact of manipulating the omega-3:omega-6 PUFA ratio
rather than focusing solely on omega-6 PUFAs. Thus, the Quantiﬁcation
of the optimal n-6/n-3 ratio in the UK Diet (OPTILIP) study involving
258 participants revealed that an omega-6:omega-3 PUFA ratio of 5:1
and 3:1 was associated with a reduction in the levels of TG and small,
dense LDL-C compared to a control diet of 10:1 ratio [54]. Overall, the
various studies highlight the need for further human trials evaluating
the role of omega-6 PUFAs on the prevention of CVD.
5. Polyphenols
Polyphenols occur naturally in plants and plant products, including
fruits, nuts, vegetables, herbs, tea and coﬀee [43,55]. Examples of
polyphenols include ﬂavonoids present in tea, cocoa and blackberries,
resveratrol in red wine, hydroxytyrosol in olives and curcumin in tur-
meric. Flavonoids have been the subject of increased recent research
and are therefore addressed separately in the next section.
Due to their abundance in edible plants and established anti-oxidant
and anti-inﬂammatory properties, there has been increased interest in
the use of polyphenols to reduce the risk of CVD [43]. Early epide-
miological studies were able to highlight the cardiovascular protective
eﬀects of polyphenols found in olives and grapes [43,55]. Since these
early studies, hundreds of polyphenol compounds have been identiﬁed
[43,55]. However the Mediterranean diet remains the gold standard for
polyphenol dietary intake and therefore a large number of investiga-
tions have focused on the polyphenols commonly found within this diet
(e.g. hydroxytyrosol) [43,55,56]. Indeed, the high concentration of
polyphenols is often associated with the anti-inﬂammatory and anti-
atherogenic actions of oils rich in monosaturated fatty acids such as
olive oil and rapeseed oil [57–59].
A human study involving 134 hypertensive subjects showed a
reduction in blood pressure following intake of polyphenol-enriched
juices (250–300mg/100 g) every day for 12 weeks when compared to
those receiving the placebo control [60]. A reduction in blood pressure
was also found in 101 hemodialysis patients, a population with a high
risk for CVD, following treatment with pomegranate juice (0.7 mM
polyphenols) three times a week for 1 year [61]. During this study,
there was also a correlation between length of treatment time and
improvements in HDL and TG levels [61]. Furthermore, the subset of
participants who had pathologically high TG levels and low HDL levels
at the start of study showed signiﬁcant improvements in these factors,
which were not observed in the placebo control [61]. However, other
studies have failed to ﬁnd an association between polyphenol intake
and reduced blood pressure [62,63]. For example, a study involving 70
patients who were either pre- or stage 1 hypertensive was unable to ﬁnd
any changes in their blood pressure compared to the placebo control
after 8 weeks of daily grape extract supplementation [62]. Another
study on 78 obese patients who were randomized to receive one of the
following diets for 8 weeks; low omega-3 PUFAs low polyphenol, high
omega-3 PUFAs low polyphenol, low omega-3 PUFAs high polyphenol,
or high omega-3 PUFAs high polyphenol, also found no changes in their
blood pressure or total and LDL cholesterol levels [63]. Those on the
high polyphenol diets did have reduced TG levels, however their HDL
plasma concentrations were also reduced [63]. Upon further analysis of
this study, there was an inverse correlation between LDL-C levels and
the intake of a speciﬁc polyphenol, gallic acid. The use of gallic acid for
the reduction of LDL-C levels therefore needs to be investigated further.
The Eﬀect of Olive Oils on Oxidative Damage in European
Populations (EUROLIVE) randomized clinical trial found a positive
correlation between the concentration of polyphenols in olive oil and
serum HDL levels in 200 healthy men following daily intervention for
3 weeks [64]. Furthermore, oxidative stress markers decreased with
increased polyphenol concentrations and TG levels were reduced in all
participants receiving olive oil [64]. The decrease in oxidative stress
markers seen in the EUROLIVE trial has since been conﬁrmed in a later
study on 117 patients with metabolic syndrome [65]. Supplementation
with polyphenols (1 g/day) in the form of curcuminoids for 8 weeks
increased their superoxide dismutase levels while simultaneously low-
ering malondialdehyde plasma concentrations, indicating reduced oxi-
dative stress [65]. In addition, those receiving curcumoids had reduced
plasma CRP levels [65]. Consistent with this study, meta-analysis of
clinical trials also revealed reduced CRP levels with curcumin though
no eﬀect was seen at the levels of plasma total cholesterol, HDL and
LDL-C [66,67]. Indeed, many animal model studies have revealed anti-
atherogenic actions of curcumin via multiple mechanisms (e.g. reduced
oxidative stress and inﬂammation, regulation of cholesterol home-
ostasis) [68].
The Prevención con Dieta Mediterránea (PREDIMED) study is the
largest trial investigating the potential cardiovascular protective eﬀects
of the Mediterranean diet [69,70]. The study involved 7172 Spanish
patients with a high risk of suﬀering from a CVD-related event. These
patients were randomized into three diﬀerent diets; Mediterranean diet
supplemented with extra virgin olive oil, Mediterranean diet supple-
mented with mixed nuts and a low-fat control diet [69,70]. Initial
analysis of the study found that after approximately 5 years, those with
the highest polyphenol intake had a 37% lower relative risk of all-cause
mortality when compared to those with the lowest polyphenol intake
[70]. Further in-depth analysis on a subset of 200 high-risk patients
found that those on the Mediterranean diet had reduced blood pressure
after 1 year compared to those on the control diet [71]. The analysis
also found a positive association between total polyphenol intake and
plasma nitric oxide (NO) levels, highlighting a possible mechanism by
which polyphenols are able to improve endothelial function, resulting
in vasodilation and a reduction in risk for CVD [71]. This improvement
in blood pressure was also found in a subset of 573 elderly participants
of the PREDIMED study after a 5-year follow-up [72]. These individuals
also had reduced plasma TG and glucose concentrations, however there
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were no changes in their total cholesterol, HDL or LDL-C levels [72].
More recently, a substudy of 1139 high-risk participants revealed re-
duced plasma levels of several inﬂammatory biomarkers related to
atherosclerosis with polyphenol intake [73]. Overall, the PREDIMED
study shows an association between the Mediterranean diet and car-
diovascular protective eﬀects by improving vascular functions and re-
ducing both blood pressure and inﬂammatory markers, rather than
altering circulating lipoproteins. Further studies are required to de-
termine the speciﬁc nutraceutical within the diet that provides the
cardiovascular health beneﬁts as the PREDIMED study provides sup-
portive rather than conclusive evidence for the use of polyphenols for
CVD. In addition, despite the potential beneﬁts of the Mediterranean
diet the PREDIMED study has uncovered, it still has its limitations; for
example, all of the participants were recruited from a single country
and therefore diﬀerences in lifestyle between countries may alter the
outcomes of the study.
6. Flavonoids
Cardiovascular protective eﬀects are frequently associated with a
high intake of fruit and vegetables that contain ﬂavonoids, which are
therefore addressed in more detail [74]. Flavonoids have generated
substantial interest because of their ability to inhibit both LDL oxida-
tion [75–77] and platelet aggregation [78]. Although vast literature
exists on anti-platelet activities of ﬂavonoids via various signaling
pathways, clinical trials have been low in numbers and produced in-
consistent results (see [78] for a recent review). In relation to anti-
oxidant activities, the Zutphen Elderly Study of 805 men aged 65–84 for
a 5-year follow-up revealed an inverse correlation between ﬂavonoid
intake and mortality from CHD together with the incidence of MI [79].
Such correlation was also found following a 10-year follow-up [80].
However, a study of 1900 Welsh men aged 45–59 years, who were
followed for 14 years, failed to reveal any protection from antioxidant
ﬂavonols, mainly from tea to which milk was added, and the incidence
of ischemic heart disease [81].
There are several subclasses of ﬂavonoids, of which the catechin
class of ﬂavanols present in cocoa and green tea have received sub-
stantial interest because of their anti-oxidant properties together with
the ability to inhibit the secretion of pro-inﬂammatory cytokines and
chemokines from activated endothelial cells [82]. This had led to the
use of ﬂavanols, particularly in the form of cocoa, in preliminary trials
in order to evaluate their eﬀectiveness in reducing CVD. A small trial
involving 27 healthy individuals on a ﬂavanol-rich diet for 5 days re-
vealed an increase in NO production which was also associated with
improved vasodilation [83]. This has subsequently been replicated in
more recent trials [84,85]. End stage renal disease (ESRD) suﬀerers
have an increased risk of CVD due to impairment of their vascular
function [86]. A trial involving 57 ESRD patients found improved
vascular function, determined by increased ﬂow-mediated dilation
(FMD), and reduced blood pressure following 30 days of cocoa ﬂavanol-
rich dietary supplementation [84]. Another population that has a high
risk of CVD is those who are overweight. Dietary intake of 814mg/day
of ﬂavanols for 4 weeks increased vasodilation in 30 overweight adults,
however there were no changes in HDL, LDL-C or total cholesterol le-
vels between those receiving ﬂavanols and the control group [85]. The
ability of ﬂavanols to increase vasodilation, potentially via ampliﬁed
NO production, highlights a possible mechanism by which they are
capable of reducing risk of CVD. A cocoa-enriched calorie restricted diet
in 50 healthy individuals has also been shown to reduce their oxLDL
levels after 4 weeks when compared to calorie restriction only [87],
another potential mechanism for cardiovascular protection by ﬂava-
nols.
Despite the positive trials mentioned above, there have been other
studies that have failed to ﬁnd any improvements in blood pressure
following ﬂavanol intake [88,89]. One trial involving 32 pre- or mild-
hypertensive men was unable to observe any changes in blood pressure
or lipid proﬁle following high daily intake of ﬂavanols (1064mg/day)
for 6 weeks [88]. A lack of reduction in blood pressure, LDL-C and total
cholesterol levels was also found in a study in which 24 healthy and 20
moderately hypercholesterolaemic patients received 30 g of cocoa per
day for 4 weeks [89]. Nevertheless, this study did detect other cardio-
vascular protective eﬀects including increased HDL levels, and a re-
duction in the level of the pro-inﬂammatory cytokine IL-1β. However, it
is worth noting that approximately 34% of the cocoa treatment was
made up of ﬁber which has also been associated with cardiovascular
health beneﬁts (discussed in Section 7 of this review), therefore the
altered levels of HDL and IL-1β in this study cannot be solely associated
to ﬂavanol intake. Overall, it is diﬃcult to draw any concrete conclu-
sions about ﬂavanols from these studies due to their limited participant
numbers, which again highlights the need for larger clinical trials.
Recently there have been three larger studies, Cocoa, Cognition and
Aging (CoCoA) [90], the Flaviola Health study [91] and PREDIMED
[69], which aimed to further investigate the potential cardio-protective
eﬀects of ﬂavanols. During the CoCoA study, 90 elderly individuals
consumed either a high (993mg), intermediate (520mg) or low
(48mg) daily ﬂavanol dose for 8 weeks [90]. At the end of the trial
those who had received either the high or intermediate daily dose of
ﬂavanols had signiﬁcant improvements in their insulin resistance,
blood pressure as well as a reduction in the amount of lipid peroxida-
tion when compared to those receiving the low ﬂavanol dose [90]. Si-
milar observations were found in the Flaviola Health study in which
100 healthy men and women without a history of CVD received 900mg
of cocoa ﬂavanol every day for 1month [91]. During the study, ﬂavanol
supplementation signiﬁcantly increased FMD and HDL levels while si-
multaneously reducing blood pressure, arterial stiﬀness as well as total
and LDL-C levels [91]. The largest observational study was the PRED-
IMED trial that involved 7172 participants whose ﬂavanol intake
ranged from 90mg/day to 263mg/day and they were followed for
approximately 4 years [69]. The study found a signiﬁcant association
between increased ﬂavanol intake and reduced CVD risk, even after
controlling for other risk factors, those on lipid lowering therapies and
other nutrients [69]. Despite these larger studies showing associations
between ﬂavanol intake and cardiovascular health beneﬁts, there is still
a need to perform larger trials which include individuals from multiple
countries, in the presence and absence of other lipid lowering therapies
in order to derive conclusive evidence for the cardiovascular protective
eﬀects of ﬂavanols in high risk individuals.
7. Dietary ﬁber, gut microbiota, prebiotics and probiotics
Many studies have revealed cardiovascular health beneﬁts of
dietary ﬁber. Meta-analysis of 10 prospective cohort studies from the
US and Europe involving 91,058 men and 245,186 women over 6 to
10 years follow-up demonstrated inverse correlation between con-
sumption of dietary ﬁber from cereals and fruits with CHD risk [92]. A
14% reduction in risk of all coronary events and a 27% decrease in risk
of coronary death were associated with each 10 g per day increase in
total dietary ﬁber intake [92]. In addition, a study involving 46,032
men over a 12-year follow-up period found an inverse association be-
tween intake of cereal ﬁber (but not fruit, vegetable and total ﬁber)
with peripheral arterial disease risk [93]. Furthermore, a study on
78,779 US women during an 18-year follow-up revealed reduced risk of
total and hemorrhagic stroke with high consumption of cereal ﬁber
[94]. However, a prospective 6-year follow-up study on 39,876 females
found reduced risk of CVD and MI with a higher intake of ﬁber though
this was not signiﬁcant after adjusting for multiple compounding fac-
tors [95]. In 116 subjects under highly eﬀective lipid-lowering therapy,
ﬁber also had no additional eﬀect on plasma lipid proﬁle but produced
other favorable outcomes such as reduction in body mass index and
blood glucose [96].
Atherosclerosis-associated changes in metabolites and inﬂammatory
markers produced by feeding a western diet to LDL receptor deﬁcient
J.W.E. Moss et al. BBA - Molecular Basis of Disease 1864 (2018) 1562–1572
1568
mice (LDLR−/−) (a mouse model of the disease) is reversed in part by
switching them to a ﬁber-rich chow diet [97]. The molecular me-
chanisms underlying such anti-inﬂammatory and -atherogenic actions
of ﬁber are poorly understood though the gut microbiota and factors
produced by them is likely to play an important role. Indeed, studies in
animals administered with prebiotics (plant-derived ﬁbers that improve
the composition and function of the gut microbiota) demonstrate anti-
atherogenic eﬀects [98,99]. For example, a study in apolipoprotein E
deﬁcient mice (ApoE−/−), another mouse model for atherosclerosis,
showed that α-cyclodextrin, which is considered as a dietary ﬁber, re-
duced the disease by modifying the gut ﬂora [99] together with other
mechanisms (e.g. increase in cholesterol solubility, cellular cholesterol
eﬄux and anti-inﬂammatory responses) [100]. Fermentation of dietary
ﬁber by gut microbiota can also generate a range of short chain fatty
acids (e.g. butyrate, acetate, propionate) with anti-atherogenic prop-
erties. In support for this, butyrate reduced plaque inﬂammation and
oxidative stress in the ApoE−/− mouse model system [101,102].
Dietary manipulation of the gut microbiota is also being explored
for the prevention of atherosclerosis though only limited studies have
been published and mechanistic understanding remains poor. L-carni-
tine, a nutrient in red meat, is metabolized by the gut microbiota to
trimethylamine that is then converted to the highly atherogenic tri-
methylamine-N-oxide (TMAO) by the host liver [103,104]. Interest-
ingly, the polyphenol resveratrol remodeled the gut microbiota in
mouse model systems to reduce TMAO-induced atherosclerosis and
enhanced fecal bile acid excretion [105]. In addition, red wine poly-
phenols modulated fecal microbiota to reduce markers of metabolic
syndrome in obese patients [106]. Probiotics (live bacteria with health
beneﬁts), particularly Lactobacilli, have also been evaluated in small
human trials and animal models. For example, meta-analysis of 15
studies with 788 subjects showed eﬀective lowering of cardiovascular
risk factors such as total cholesterol, LDL-C and inﬂammatory markers
[107], conclusions that are supported by another similar meta-analysis
[108]. Studies in mouse model systems have also shown attenuation of
atherosclerosis by probiotic bacteria via multiple mechanisms, in-
cluding induction of tolerogenic dendritic cells [109], stimulation of
cholesterol eﬄux [110] and reduction in both intestinal cholesterol
uptake and vascular inﬂammation [111,112].
8. Other nutraceuticals
There are several other nutraceuticals that have been less well
studied so will only be mentioned brieﬂy here with focus on outcomes
from animal models and clinical trials (Table 2). Allicin, the primary
active ingredient in garlic, attenuated atherosclerosis in both the
LDLR−/− and ApoE−/−model systems by acting as an antioxidant, and
inhibiting LDL uptake and degradation by macrophages [113]. How-
ever, meta-analysis of 45 trials showed that garlic supplementation
produced only short-term (1–3months) reduction in plasma levels of
total cholesterol, LDL-C and TG with no eﬀect on blood pressure or
glucose levels [114]. Berberine, a plant alkaloid, also reduced plaque
size and vulnerability, inﬂammation and oxidative stress in ApoE−/−
mice [115,116]. Clinical trials have been small (63–144 patients) but
demonstrated reduced plasma levels of total cholesterol and LDL-C via a
mechanism involving increased LDLR mRNA stability [117–119].
However, the bioavailability of berberine is very poor (< 1%) [120].
Although carnosine, an antioxidant peptide commonly found in meat,
attenuated atherosclerosis in ApoE−/− mice by lowering levels of TG
and reducing vascular inﬂammation and foam cell formation
[121–123], a small pilot study in 15 humans found no changes in blood
pressure or serum levels of cholesterol and CRP [124]. For lycopene, a
carotenoid found in tomatoes and other red fruit and vegetables, two
systematic reviews and meta-analysis published in 2017 showed that
higher intake is associated with a lower risk of CVD due to reduction in
LDL-C, pro-inﬂammatory cytokines and blood pressure, and improved
FMD [125,126]. Coenzyme Q10 (CoQ10), an anti-oxidant and
component of the electron transport chain whose de novo synthesis is
reduced by statin therapy, attenuated atherosclerosis in the ApoE−/−
model system by promoting macrophage cholesterol eﬄux [127],
which was also conﬁrmed in a pilot study on 20 healthy volunteers
[128]. A meta-analysis involving 194 patients also demonstrated sig-
niﬁcant improvement of endothelial function with CoQ10 supple-
mentation [129].
Phytosterols, plant sterols and stanols, are believed to mediate
cardio-protective actions by competing with cholesterol in the intestinal
lumen during dietary and biliary cholesterol uptake. For phytosterols,
an epidemiological study involving 22,256 individuals showed corre-
lations between diets with high levels and reduced plasma LDL-C con-
centration [130]. A meta-analysis of 41 trials showed about 10% low-
ering of LDL-C by intake of 2 g per day of phytosterols with eﬀects being
additive with intervention by drugs or diet [131]. For example, a 20%
reduction in plasma LDL-C was found by diets high in phytosterols and
low in saturated fats and cholesterol [131]. Adding phytosterols to
statins was also found to be more eﬀective than doubling the dose of the
latter [131]. Although this study failed to see any additional reduction
in LDL-C with intakes of phytosterols above 2 g per day, this has been
observed in other studies [132,133]. More recently, meta-analysis in-
volving 1308 subjects showed an association between phytosterol in-
take and reduced plasma LDL-C levels but no changes in plasma CRP
[134]. On the basis of such promising outcomes, several guidelines
recommend daily intake of 2 g of plant sterols and/or stanols to reduce
LDL-C levels [135]. Foods enriched with phytosterols (e.g. margarine)
are often taken to achieve these recommended levels because western
diets typically contain about 300mg/day of phytosterols [135]. Phy-
tosterols also attenuate atherosclerosis in mouse model systems by re-
ducing inﬂammation and plasma cholesterol levels, and increasing HDL
[136,137]. However, this has not been replicated in humans with some
concerns raised on the beneﬁcial eﬀects of food supplementation with
phytosterols (see [135,138,139] for recent reviews), emphasizing the
need for further research and large trials.
9. Conclusions
Nutraceuticals represent promising agents in the prevention and
treatment of atherosclerosis as demonstrated by both preclinical and
clinical studies. More research is essential given that current therapies
are not fully eﬀective and many promising pharmaceutical leads have
failed at the clinical level. However, research on nutraceuticals have
lagged considerably behind pharmaceuticals on several aspects: (i)
large, controlled clinical trials on a scale at least similar to the REDUCE-
IT and STRENGTH trials currently under way for omega-3 PUFA sup-
plementation and possibly on the scale of major pharmaceuticals such
as ezetimibe and PCSK9 antibodies; (ii) pre-clinical studies that use
concentrations within the physiological level (most use very high
doses), could be easily translated to humans (many are carried out on
mice that show diﬀerences to humans in two key aspects of CVD, lipid
metabolism and the inﬂammatory response) and also incorporate dose-
response experiments whenever possible. In addition, it is essential that
there is consistency in human studies in relation to composition, dose of
agent and duration of intervention in order to reduce the signiﬁcant
level of discrepancy that often exists in published literature on nu-
traceutical actions and eﬃcacy. Deeper insight into the mechanisms
underlying nutraceutical actions is also required as they could inform
on the development of potent pharmacological agents that mimic key
responses. For example, studies on omega-3 fatty acids revealed that
GPR120 was the receptor that mediated its potent anti-inﬂammatory
and insulin sensitizing eﬀects [140]. Further research demonstrated
that a selective high-aﬃnity, orally available, small molecule GPR120
agonist (cpdA) improved insulin resistance and chronic inﬂammation in
obese mice [141]. We are indeed entering an exciting phase in nu-
traceutical research.
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